Camlin Fine Sciences , a key player in the Indian chemical sector, has successfully completed the postal ballot process for the re-appointment of its Independent Director, with shareholders overwhelmingly approving the proposal with official results now confirmed.

Postal Ballot Results

The postal ballot voting concluded on December 13, 2025, with shareholders approving the re-appointment of Mr. Mahabaleshwar G. Palekar as Non-Executive Independent Director for a second five-year term. The official voting results demonstrate exceptional shareholder confidence in the leadership decision.

Director Re-appointment Details

Mr. Mahabaleshwar G. Palekar (DIN: 02455892) has been re-appointed as Non-Executive Independent Director for a second term of five consecutive years, commencing from December 24, 2025, to December 23, 2030. The appointment was processed through remote e-voting facility provided by National Securities Depository Limited (NSDL).

Category-wise Voting Breakdown

The detailed voting results across different shareholder categories show strong support across all segments:

Voting Process and Compliance

The postal ballot process was conducted in accordance with Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. S.J. Ranade, Partner of JHR Associates, served as the scrutinizer for the voting process and submitted the official scrutinizer report on December 15, 2025.

Corporate Governance Initiatives

The overwhelming approval of Mr. Palekar's re-appointment reflects strong shareholder confidence in the company's leadership and governance structure, supporting Camlin Fine Sciences' long-term strategic objectives. The company continues to maintain high standards of corporate governance with transparent voting processes and comprehensive disclosure requirements.

Camlin Fine Sciences Limited has received Indian regulatory approvals for its proposed acquisition of a majority stake in French company Vinpai S.A. The approval, granted on November 18, 2025, comes with an adjusted timeline for the completion of the transaction.

Shareholder Approval and Offer Details

The company announced that shareholders have overwhelmingly approved the transaction, with 99.99% of votes in favor. The acquisition is set to proceed at a price of EUR 3.60 per share.

Revised Timeline

Following the regulatory approval, Camlin Fine Sciences has adjusted its acquisition timeline:

• Allotment of consideration shares is now scheduled by November 30, 2025
• Filing of the simplified tender offer is planned for mid-December 2025

This new schedule represents a shift from the earlier target completion date of September 30, 2025, which was announced in a previous update on June 25, 2025.

Reasons for the Earlier Delay

The initial delay was attributed to documentation requirements for foreign sellers involved in the transaction. Specifically, the foreign national sellers needed to obtain Permanent Account Numbers (PANs), a prerequisite for preferential allotment under Securities and Exchange Board of India (SEBI) regulations.

Progress and Next Steps

With the regulatory approvals now in place and the timeline adjusted, Camlin Fine Sciences is moving forward with the next phases of the acquisition process. The company is likely to proceed with the issuance of equity shares through preferential allotment as payment for acquiring the majority stake in Vinpai via a share swap arrangement.

Background of the Acquisition

The proposed acquisition was initially disclosed on February 24, 2025, when Camlin Fine Sciences executed a Share Purchase Agreement (SPA) with certain significant shareholders of Vinpai, including its founders.

Regulatory Compliance

Camlin Fine Sciences has assured stakeholders that it is adhering to all necessary regulatory requirements. The company has been providing relevant details as mandated under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

As Camlin Fine Sciences progresses with its plans to acquire a majority stake in Vinpai S.A., investors and industry observers will be watching for further developments in this strategic move. The successful navigation of regulatory approvals marks a significant milestone in this cross-border transaction, setting the stage for the final phases of the acquisition process.